Plus, a Top 1% analyst weighs in on Wall Street's biggest stock.
Plus, a Top 1% UBS stock picker sees almost 50% upside on this chipmaker, and more.
Plus, the 9th best analyst on Wall Street's favorite AI call, and more.
One stock pick from a top-ranked analyst with an implied upside of 100% or more.
Plus, the latest ticker from a Wall Street analyst with +186% average returns, a Top 1% analyst's take on Tesla, and more.
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
The market may be missing a protein upgrade that favors eggs.
Plus, a firm with three hyperscale leases signed, a biotech with four drugs on market, and a stock down 29% that activists just shook up.
Plus, a chipmaker guiding to 903% earnings growth, a gene therapy stock one top 2% analyst gives 170% upside, and more.
Plus, a quiet winner of the US defense budget, a COVID-era darling due for a resurgence, and a top-tier analyst’s contrarian call carrying more than 100% upside potential.
Plus, a beaten-down enterprise play with more than 100% upside potential, a bitcoin miner with a repositioning plan that caught the eye of a Top 1% analyst, and more.
Here’s everything you might have missed last week on Wall Street, and everything to watch in the week ahead.
A below-the-signal beneficiary of the fiber revolution.
Plus, an unexpected beneficiary of a dead deal, a post-AI-selloff dip-buying opportunity, and a high-upside-potential call from an analyst with an average return of more than 80%.
